No Proven Oral Alternative to Acetazolamide for Normal Pressure Hydrocephalus
Unfortunately, there is no established alternative oral medication to replace acetazolamide (Azomid) for normal pressure hydrocephalus (NPH), and the evidence for acetazolamide itself in NPH is extremely limited and now contradicted by recent high-quality data.
Critical Evidence Against Acetazolamide in NPH
The most recent and highest-quality evidence—a 2026 randomized, double-blind, placebo-controlled trial (DRAIN study)—definitively showed that acetazolamide did not improve gait compared to placebo in NPH patients 1. More concerning, 36% of patients discontinued acetazolamide due to adverse events (including the paresthesias your patient is experiencing) versus only 8% with placebo 1. This represents the strongest evidence available and directly contradicts the use of acetazolamide for NPH.
Why Paresthesias Occur
The pins-and-needles sensation your patient experiences is a well-documented side effect of acetazolamide, occurring due to its carbonic anhydrase inhibition causing metabolic acidosis and electrolyte disturbances 2, 3. This is not an idiosyncratic reaction but rather a predictable pharmacological effect.
The Reality of NPH Treatment
Surgical CSF diversion (ventriculoperitoneal shunt or endoscopic third ventriculostomy) remains the only proven effective treatment for NPH 4, 5. The evidence base is clear:
- No pharmacological agent has proven effective for NPH 1, 5
- Historical use of acetazolamide in NPH was based on theoretical rationale (reducing CSF production) rather than clinical evidence 6, 5
- A 2012 study in neonatal posthemorrhagic hydrocephalus showed acetazolamide combined with furosemide actually increased mortality and neurological morbidity 7
Alternatives That Have Been Studied (But Lack Evidence)
While the following have been investigated, none have proven efficacy for NPH:
Furosemide (Loop Diuretic)
- Theoretically reduces CSF production
- Often combined with acetazolamide historically 6
- No evidence of benefit in NPH specifically
- Would not avoid the side effect profile your patient is experiencing
Topiramate
- Has carbonic anhydrase inhibitor properties similar to acetazolamide
- Recent 2026 data shows promise in idiopathic intracranial hypertension (a different condition) 8, 9
- No evidence for use in NPH
- Would likely cause similar paresthesias as it shares the same mechanism
Isosorbide (Osmotic Agent)
Clinical Recommendation
Given your patient's intolerable side effects and the lack of evidence for acetazolamide's efficacy in NPH, you should:
Discontinue acetazolamide - The DRAIN trial shows it doesn't work and causes significant adverse effects 1
Refer for neurosurgical evaluation if not already done - Shunt surgery remains the only evidence-based treatment for symptomatic NPH 4, 5
Do not substitute another oral medication - No alternative has proven benefit, and you risk exposing the patient to additional side effects without therapeutic gain
Manage symptoms supportively while awaiting definitive surgical intervention
Important Caveat
The evidence cited above for acetazolamide in other conditions (central sleep apnea 2, idiopathic intracranial hypertension 8, 9, coccidioidal meningitis with hydrocephalus [@3-5,10,11]) does not apply to NPH. These are distinct pathophysiological entities requiring different management approaches.
The paresthesias will resolve after discontinuing acetazolamide, typically within days to weeks as the drug is eliminated [@13@, @14